.png){kind=icon}
.png){kind=icon}
Return
Selective histone deacetylase inhibition as a therapeutically relevant strategy in H3K27M-glioma
.png){kind=icon}
OA
AI
A
O
C
X
C
J
C
R
T
D
Y
Q
H
S
M
J
G
K
A
L
B
Q
B
M
J
DOI：10.1093/neuonc/noag142.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Diffuse midline glioma (DMG) is a lethal pediatric brain tumor, driven by profound epigenetic dysregulation, raising the possibility that targeting epigenetic regulators such as histone deacetylases (HDACs) could provide a therapeutic benefit. However, despite preclinical activity, currently available HDAC inhibitors have shown limited clinical translation due to poor central nervous system (CNS) penetration and a lack of HDAC isoform selectivity.
Journal
N
IF:
13.4
Papers:
1.2W
Citations:
2.5W
Organization
Cited Papers